CD274 and neoplasm: Recent data suggest weak utility of PD‐L1 tumor status as malignancies with low PD‐L1 expression may still respond to ICI therapy, albeit at a lower rate, perhaps due to heterogeneity of PD‐L1 expression throughout tumor tissue or differing PD‐L1 expression detection methods and cut‐off criteria.2